A new article published in the journal Nature is reporting promising results from a landmark Phase 1 human trial testing a novel vaccine designed to help a patient’s immune system better target brain tumors. The data suggests the experimental vaccine is safe and stimulates a significant immune response that slows tumor progression. A larger Phase 2 trial is currently being planned.
Glioblastomas are highly aggressive brain tumors that are notoriously difficult to treat, with the cancer cells often slipping away from the main growth and into the brain, leading to high rates of recurrence down the track. In search of more effective therapies, scientists are investigating how the cell-destroying abilities of certain viruses can be leveraged to better remove the threat. A team at Yale University is now reporting an exciting breakthrough in this area, with components of the Ebola virus put to use in a promising new therapy that proved capable of killing glioblastomas in mice.
Glioblastoma is one of the most deadly forms of cancer. Affecting the brain, those unlucky enough to receive a diagnosis don’t have many treatment options – and usually a median life expectancy of just over a year. Now, researchers at MIT have developed nanoparticles that could provide hope, crossing the blood-brain barrier and delivering two types of drugs to fight tumors.